Novartis-GEM Melanoma Challenges
GEM and Novartis launch two challenges to the entrepreneurial ecosystem to identify digital projects that improve the health and quality of life of patients with melanoma.
What is the Novartis-GEM Melanoma challenge?
This program aims to identify initiatives that can respond to existing needs in the management of melanoma. To do this, they have launched two challenges to the entrepreneurial ecosystem.
The projects with the greatest potential for each challenge will be presented and evaluated based on their feasibility, feasibility and adaptability, jointly by Novartis, GEM and specialized mentors from Connector in a pitching session.
- Health professionals
- Investigation groups
- All those interested in developing a digital project to transform the lives of patients
Who can apply to the call?
About the prizes and bases of the program
The two winning projects will receive an economic prize of € 3,000 each to promote the development of their model and they will have the possibility to access an acceleration program or to carry out a proof of concept, depending on the phase in which the project is.
In both cases, they will be supported and monitored by an innovation committee made up of a group of high-level mentors from GEM, Novartis and the Conector network, who will share their experience to support and optimize the development of their business models.
The jury will assess the solutions proposed by the startups, it is made up of two Novartis executives, two members of the GEM board of directors and one Connector, who will choose the two projects that best solve the challenges proposed according to the bases of the program.
Novartis is reimagining medicine in order to improve and prolong people’s lives. As the world’s leading drug development company, we use science-based innovation and digital technologies to develop disruptive therapies in areas with underserved medical needs. In our mission to discover new drugs, we rank among the best companies in the world in terms of investment in research and development.
Novartis products reach more than 750 million people globally and we strive to find innovative ways to expand access to our treatments. More than 110,000 people of more than 140 nationalities work at Novartis globally.
TheGrupo Español Multidisciplinar de Melanoma(GEM) is an association that was born with the aim of joining and coordinating efforts between health professionals who treat melanoma.
The group aims to offer the best treatments to people suffering from melanoma, while collecting new ideas and research proposals, with special emphasis on those that are able to advance in the treatment of metastatic diseases.
GEM is a cooperative and multidisciplinary group, therefore those health professionals who can make contributions in the fight against melanoma are welcome. Thus, it is an initiative open to all specialists who care for these patients.